Preclinical studies, in which a deletion of galectin-3-encoding gene was used, demonstrated the role of galectin-3 on the long list of cardiovascular diseases, including those focused on heart remodelling [106,107], hyperaldosteronism and arterial hypertension [108,109], acute myocardial infarction [110], myocardial ischemic/reperfusion injuries [111] and dilated cardiomyopathy [112]. This evidence concerns the gene LGALS3 and hyperaldosteronism.